Incannex Healthcare Inc. (IXHL) stock
Close on Nov 12, 2026Market cap $25.34MP/E –Yield –
Incannex Healthcare Inc. saw revenue fall 100.0% to $0 over fiscal 2026. Free cash flow was -$12.88M. At the latest close the market valued the company at $25.34M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2026, balances at Jun 30, 2026
Valuation
- Market cap
- $25.34M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.38
- Dividend yield
- –
- Free cash flow yield
- -50.82%
Fundamentals
- Revenue
- $0
- Net income
- -$19.30M
- EPS, diluted
- -$1.66
- Free cash flow
- -$12.88M
- Book value per share
- $5.49
- Diluted shares
- 12M
Trading
- Previous close
- $1.98
- Open
- $1.96
- Day's range
- $1.96 – $2.06
- Volume
- 104,350
- Average volume (20 days)
- 81,250
- Beta (5 years)
- 1.94
- 52-week range
- $1.96 – $14.91
- RSI (14 days)
- 23.7
- Volatility (1 year)
- 103.5%
- Relative volume
- 1.07×
- WACC
- 14.7%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | IXHL | S&P 500 | Difference | IXHL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -30.3% | -2.7% | −27.6 pts | ||
| 3 months | -36.3% | -1.7% | −34.5 pts | ||
| Year to date | -81.2% | +11.9% | −93.1 pts | ||
| 1 year | -81.9% | +12.0% | −93.9 pts | ||
| 3 years | -98.5% | +78.2% | −176.7 pts | -75.3% | +21.2% |
Seven years at a glance
Fiscal years 2020 to 2026, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Incannex Healthcare filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About Incannex Healthcare
Pharmaceutical Preparations
Incannex is a clinical-stage biopharmaceutical company developing oral fixed-dose combination therapies and psychedelic-assisted treatments for serious, chronic conditions. Its pipeline includes IHL-42X, an oral combination therapy in clinical development for obstructive sleep apnea, and PSX-001, a synthetic psilocybin treatment administered alongside psychotherapy for generalized anxiety disorder. The company is also evaluating IHL-675A, an oral combination targeting inflammatory conditions including rheumatoid arthritis. These investigational programs aim to provide alternative pharmacological treatments for patients who are underserved by existing care options.
Company profile, executives and historyIncannex Healthcare stock: common questions
What is Incannex Healthcare's stock price?
IXHL closed at $2.02 on Nov 12, 2026, up 2.28% on the day. Over the past 52 weeks it traded between $1.96 and $14.91.
What is Incannex Healthcare's market cap?
Incannex Healthcare was worth $25.34M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is IXHL's P/E ratio?
Incannex Healthcare lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.66), so it has no meaningful P/E ratio.
How much revenue does Incannex Healthcare make?
Incannex Healthcare reported revenue of $0 for fiscal 2026, down 100.0% from a year earlier.
Does Incannex Healthcare pay a dividend?
No. Incannex Healthcare has not paid a cash dividend over the last twelve months.
How has IXHL stock performed over the past year?
Including dividends, IXHL returned -81.9% over the past year, against +12.0% for the S&P 500.
Who are Incannex Healthcare's competitors?
Companies most similar to Incannex Healthcare by business, industry and size include KZIA, CNBX, LSTA, SILO, HIND.
See a number that looks wrong?